On Thursday, JB Chemicals & Pharmaceuticals announced that its board has given the green light to a proposal for acquiring four pediatric brands from Dr. Reddy’s Laboratories, amounting to approximately Rs 98 crore. During its meeting on June 29, the board reviewed and sanctioned the acquisition of a brand portfolio designed for sales within India from Dr. Reddy’s Laboratories, as outlined in a regulatory filing by the pharmaceutical company.
JB Chemicals & Pharmaceuticals has entered into an agreement with Dr. Reddy’s Laboratories to procure four brands—Z&D, Pedicloryl, Pecef, and Ezinapi—targeting the Indian market. These brands exclusively cater to the pediatric segment in the country, with a combined market size of Rs 1,800 crore according to IQVIA data, as highlighted by JB Chemicals & Pharmaceuticals.
The cumulative sales for these brands in the fiscal year 2021-22 amounted to approximately Rs 33 crore, the company noted. The acquisition, primarily financed through long-term debt, is slated to conclude in the coming working days, according to the pharmaceutical firm.